EUDA Signs Letter of Intent to Potentially Acquire GO POSB
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent to potentially acquire GO POSB Organoids, a Singapore biotechnology company. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that converts human blood cells into clinical-grade stem cells.
The companies plan to establish an iPSC laboratory and cultivation facility in Shenzhen, China, collaborating with Singapore's A*STAR for research and clinical trials. The facility aims to serve as a distribution hub for iPSC solutions across China, pending regulatory approvals. The initiative aligns with EUDA's strategy to expand its stem cell treatments and supplements portfolio.
EUDA Health Holdings (NASDAQ: EUDA), fornitore di servizi sanitari con sede a Singapore, ha firmato una Lettera d'Intenti per l'eventuale acquisizione di GO POSB Organoids, società biotecnologica di Singapore. GO POSB ha sviluppato una piattaforma proprietaria di cellule staminali pluripotenti indotte (iPSC) che trasforma cellule del sangue umano in cellule staminali di grado clinico.
Le aziende intendono creare un laboratorio e una struttura di coltura iPSC a Shenzhen, Cina, collaborando con l'A*STAR di Singapore per attività di ricerca e sperimentazione clinica. La struttura dovrebbe fungere da hub distributivo per soluzioni iPSC in tutta la Cina, soggetta alle approvazioni normative. L'iniziativa è in linea con la strategia di EUDA di espandere il proprio portafoglio di trattamenti a base di cellule staminali e integratori.
EUDA Health Holdings (NASDAQ: EUDA), proveedor de servicios sanitarios con sede en Singapur, ha firmado una Carta de Intención para la posible adquisición de GO POSB Organoids, una empresa biotecnológica de Singapur. GO POSB ha desarrollado una plataforma propia de células madre pluripotentes inducidas (iPSC) que convierte células sanguíneas humanas en células madre de calidad clínica.
Las compañías planean establecer un laboratorio y una instalación de cultivo iPSC en Shenzhen, China, colaborando con A*STAR de Singapur para la investigación y los ensayos clínicos. La instalación tiene como objetivo actuar como centro de distribución de soluciones iPSC en toda China, sujeto a aprobaciones regulatorias. La iniciativa se alinea con la estrategia de EUDA de ampliar su cartera de tratamientos con células madre y suplementos.
EUDA Health Holdings (NASDAQ: EUDA), 싱가포르에 본사를 둔 의료 서비스 제공업체가 싱가포르 생명공학 기업인 GO POSB Organoids의 잠재적 인수를 위한 양해각서(LOI)를 체결했습니다. GO POSB는 인간 혈액 세포를 임상 등급의 줄기세포로 전환하는 자체 유도 만능줄기세포(iPSC) 플랫폼을 개발했습니다.
양사는 중국 선전에서 iPSC 실험실 및 배양 시설을 설립하고, 연구 및 임상시험을 위해 싱가포르의 A*STAR와 협력할 계획입니다. 이 시설은 규제 승인에 따라 중국 전역에 iPSC 솔루션을 공급하는 유통 허브 역할을 목표로 합니다. 이 사업은 EUDA가 줄기세포 치료제 및 보충제 포트폴리오를 확장하려는 전략과 일치합니다.
EUDA Health Holdings (NASDAQ: EUDA), prestataire de soins basé à Singapour, a signé une lettre d'intention en vue de l'acquisition potentielle de GO POSB Organoids, une société de biotechnologie singapourienne. GO POSB a mis au point une plateforme propriétaire de cellules souches pluripotentes induites (iPSC) qui convertit des cellules sanguines humaines en cellules souches de qualité clinique.
Les sociétés prévoient d'établir un laboratoire iPSC et une installation de culture à Shenzhen, en Chine, en collaboration avec A*STAR de Singapour pour la recherche et les essais cliniques. L'installation vise à servir de centre de distribution de solutions iPSC à travers la Chine, sous réserve des approbations réglementaires. Cette initiative s'inscrit dans la stratégie d'EUDA d'élargir son portefeuille de traitements par cellules souches et de compléments.
EUDA Health Holdings (NASDAQ: EUDA), ein in Singapur ansässiger Gesundheitsdienstleister, hat eine Absichtserklärung zum möglichen Erwerb von GO POSB Organoids, einem Biotechnologieunternehmen aus Singapur, unterzeichnet. GO POSB hat eine proprietäre Plattform für induzierte pluripotente Stammzellen (iPSC) entwickelt, die menschliche Blutzellen in klinisch verwendbare Stammzellen umwandelt.
Die Unternehmen planen die Einrichtung eines iPSC-Labors und einer Kultivierungsanlage in Shenzhen, China und kooperieren hierfür mit Singapurs A*STAR für Forschung und klinische Studien. Die Anlage soll, vorbehaltlich behördlicher Genehmigungen, als Verteilzentrum für iPSC-Lösungen in ganz China dienen. Die Initiative passt zu EUDAs Strategie, das Portfolio an Stammzelltherapien und Nahrungsergänzungsmitteln auszubauen.
- Strategic expansion into the promising iPSC biotechnology sector
- Potential to establish a state-of-the-art iPSC facility in Shenzhen, China
- Partnership with Singapore's A*STAR for research and clinical trials
- Access to B2B opportunities in healthcare ecosystem and wellness markets
- Acquisition is still in LOI phase with no guaranteed completion
- Requires significant regulatory approvals in China
- No financial terms or investment requirements disclosed
- Implementation and facility development timeline uncertainties
Insights
EUDA's potential acquisition of GO POSB expands into promising iPSC technology, though commercial viability remains uncertain.
EUDA Health's letter of intent to acquire GO POSB Organoids represents a strategic expansion into the induced pluripotent stem cell (iPSC) technology space. GO POSB's proprietary platform for reprogramming human blood cells into therapeutics-ready stem cells addresses a crucial bottleneck in regenerative medicine – creating pluripotent cells without ethical concerns associated with embryonic sources.
The planned iPSC laboratory in Shenzhen would position EUDA as a B2B supplier of stem cell solutions across China's healthcare ecosystem, including hospitals and biotech developers. This vertical integration into the regenerative medicine supply chain could create multiple revenue streams – from clinical applications to consumer-facing wellness products like hair rejuvenation treatments.
However, this remains only a letter of intent, not a finalized acquisition. The technical complexity of scaling iPSC production, securing Chinese regulatory approvals, and commercializing novel cell therapies presents significant execution challenges. While collaborating with Singapore's A*STAR provides valuable scientific validation, the path from laboratory to commercial viability in regenerative medicine typically spans 5-10 years with substantial capital requirements.
The strategic alignment with EUDA's existing stem cell treatments appears logical, but investors should recognize that iPSC technology, while promising, still faces regulatory and commercialization hurdles before meaningful revenue generation.
SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore.
GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical concerns linked to embryonic stem cells, making them one of the most promising frontiers in biotechnology.
Strategic Expansion into iPSC Solutions
Under the LOI, EUDA and GO POSB are exploring the establishment of a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China. The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals. EUDA will provide funding for the build-out while the two companies collaborate with Singapore’s Agency for Science, Technology and Research (A*STAR) to advance iPSC research, conduct clinical trials, and accelerate regulatory pathways for therapeutic applications.
The collaboration will position EUDA to supply B2B iPSC solutions to the downstream healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond core therapeutic applications, the platform also opens future opportunities for off-the-shelf iPSC-derived product lines tailored for Asia’s wellness and aesthetics markets, such as iPSC-based hair rejuvenation and facial treatments. These initiatives are designed to directly complement EUDA’s growing portfolio of stem cell treatments and supplements, reinforcing the Company’s integrated approach to longevity and regenerative health.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Go POSB, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
FAQ
What is the purpose of EUDA's potential acquisition of GO POSB?
What are the main features of GO POSB's iPSC technology?
Where will EUDA and GO POSB establish their iPSC facility?
What is the current status of EUDA's acquisition of GO POSB?
How does this acquisition align with EUDA's business strategy?
